Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Winslow Capital Management LLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,177,439 shares of the biopharmaceutical company’s stock after selling 9,739 shares during the period. Alnylam Pharmaceuticals accounts for approximately 1.3% of Winslow Capital Management LLC’s holdings, making the stock its 26th largest position. Winslow Capital Management LLC owned about 0.90% of Alnylam Pharmaceuticals worth $383,951,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALNY. WINTON GROUP Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $1,152,000. California Public Employees Retirement System lifted its holdings in Alnylam Pharmaceuticals by 5.0% during the 2nd quarter. California Public Employees Retirement System now owns 211,581 shares of the biopharmaceutical company’s stock valued at $68,994,000 after purchasing an additional 10,100 shares during the last quarter. Federated Hermes Inc. boosted its position in Alnylam Pharmaceuticals by 22.6% during the second quarter. Federated Hermes Inc. now owns 323,842 shares of the biopharmaceutical company’s stock worth $105,602,000 after purchasing an additional 59,669 shares during the period. Jump Financial LLC increased its holdings in shares of Alnylam Pharmaceuticals by 9.3% in the second quarter. Jump Financial LLC now owns 17,177 shares of the biopharmaceutical company’s stock valued at $5,601,000 after purchasing an additional 1,460 shares during the last quarter. Finally, Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $241,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $458.12 on Monday. The business has a fifty day moving average price of $456.78 and a two-hundred day moving average price of $403.79. The stock has a market capitalization of $60.52 billion, a PE ratio of 1,908.83 and a beta of 0.30. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Insider Activity

In related news, EVP Tolga Tanguler sold 1,405 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the transaction, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 10,000 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total value of $4,512,700.00. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,517,119.43. The trade was a 13.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 78,328 shares of company stock valued at $35,705,793. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ALNY. Royal Bank Of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Evercore ISI lifted their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Stifel Nicolaus boosted their price target on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Finally, Oppenheimer reiterated an “outperform” rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.